Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Nov;75(11):e14578.
doi: 10.1111/ijcp.14578. Epub 2021 Jul 12.

The association between apolipoprotein A-1 plasma level and premature coronary artery disease: A systematic review and meta-analysis

Mohammad Haji Aghajani  1   2 , Arian Madani Neishaboori  3 , Koohyar Ahmadzadeh  3 , Amirmohammad Toloui  3 , Mahmoud Yousefifard  3
Affiliations
Meta-Analysis

The association between apolipoprotein A-1 plasma level and premature coronary artery disease: A systematic review and meta-analysis

Mohammad Haji Aghajani et al. Int J Clin Pract. 2021 Nov.

Abstract

Background: Apolipoprotein A-1 (Apo A-1) is a constituent of high-density lipoprotein (HDL) and emerging evidences put forward a potential association between Apo A-1 plasma levels and premature coronary artery disease (pCAD). The aim of the present study is to gather relative literature and perform a systematic review and meta-analysis regarding the association between serum ApoA-1 levels and pCAD.

Methods: Medline (via PubMed), Scopus, Embase and Web of Science databases were searched from the inception of databases until December 7, 2020. All articles reporting the plasma levels of ApoA-1 in patients with pCAD and the control group were included. A meta-analysis with pooled standardised mean difference (SMD) and 95% confidence interval (95% CI) was reported. Subgroup analyses were done based on the observed heterogeneity in results.

Results: Seventeen case-control studies were included. ApoA-1 plasma level was calculated to be lower in pCAD patients compared with the control group (SMD: -0.67; 95% CI: -0.48 to -0.86; P < .001). The subgroup analysis and meta-regression showed that the variation in gender distribution, the development level of the target population's country and quality score of included studies were the main sources of heterogeneity. It was observed that the relationship was only significant in the developed countries (P < .001). Also, the heterogeneity was reduced when the analysis was limited to males (I2 = 57.2%) and females only (I2 = 26.0%).

Conclusion: In conclusion, there seems to be a significant association between the serum levels of ApoA-1 and pCAD. However, all of the included studies had a case-control design and since there is no good quality and prospective cohort studies included, reliability of the current evidence is debatable. Therefore, further well-designed cohort studies are required to assess the impact of serum ApoA-1 reduction on pCAD onset.

PubMed Disclaimer

References

REFERENCES

    1. Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76:2982-3021.
    1. Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke Statistics-2019 update a report from the American Heart Association. Circulation. 2019;139:e56-e528.
    1. Fryar CD, Chen T-C, Li X. Prevalence of uncontrolled risk factors for cardiovascular disease: United States, 1999-2010. NCHS Data Brief. 2012;103:1-8.
    1. WHO. WHO reveals leading causes of death and disability worldwide: 2000-2019. 2020. Available from: https://www.who.int/news/item/09-12-2020-who-reveals-leading-causes-of-d....
    1. Yusuf S, Joseph P, Rangarajan S, et al. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet. 2020;395:795-808.

LinkOut - more resources